Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21049510 | 0.83 | HTT (0.42) | HTTHTR1DHTR1BPOLBALDH1A1 | |
| SCHEMBL12214120 | 0.81 | KDM4E (0.42) | HTR1DHTR1BLMNAKDM4EMAPT | |
| SCHEMBL8148463 | 0.81 | HTR1D (0.67) | HTTHTR1DHTR1BLMNAMAPT | |
| SCHEMBL6017716 | 0.80 | GPR17 (0.41) | HTTHTR1DLMNAKDM4EMAPT | |
| SCHEMBL8712162 | 0.79 | HTT (0.40) | HTTHTR1DHTR1BKDM4EGAA | |
| SCHEMBL3476152 | 0.79 | KDM4E (0.41) | HTR1DHTR1BLMNAKDM4EMAPT | |
| SCHEMBL509440 | 0.79 | KDM4E (0.58) | LMNAKDM4EMAPTPOLBALDH1A1 | |
| SCHEMBL1259503 | 0.79 | KDM4E (0.41) | HTR1DHTR1BLMNAKDM4EMAPT | |
| SCHEMBL3001388 | 0.78 | HTT (0.42) | HTTLMNAMAPTPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL7983275 | 0.78 | HTT (0.39) | HTTHTR1DHTR1BKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113462278-B | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-113462278-A | Varnish composition, method for producing polyimide resin, and additive | 东京应化工业株式会社 | 2021-10-01 | — | — | CN | disclosed |
| EP-3455220-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| CN-106000465-B | A kind of method of aldehyde and the oxidative coupling reaction of two level amide | 苏州大学 | 2018-07-31 | — | — | CN | disclosed |
| WO-2017195149-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-16 | — | — | WO | disclosed |
| CN-106279211-A | A kind of thiazolopyrimidinone compound and its preparation method and application | 北京大学 | 2017-01-04 | — | — | CN | disclosed |
| CN-106000465-A | Method for oxidative coupling reaction of aldehyde and secondary amide | 苏州大学 | 2016-10-12 | — | — | CN | disclosed |
| CN-103402979-B | Chemical compound | 先正达参股股份有限公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120069418-A1 | ELECTROCHROMIC FORMULATION, METHOD FOR THE PRODUCTION THEREOF, AND ORGANIC ELECTROCHROMIC COMPONENT | SIEMENS AKTIENGESELLSCHAFT (DE) | 2012-03-22 | — | — | US | disclosed |
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2010136267-A1 | ELECTROCHROMIC FORMULATION, METHOD FOR THE PRODUCTION THEREOF, AND ORGANIC ELECTROCHROMIC COMPONENT | SIEMENS AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | HTT 3178/4885HTR1D 4672/4885HTR1B 4042/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | HTT 3178/4885HTR1D 4672/4885HTR1B 4042/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | HTT 3625/4885HTR1D 4155/4885HTR1B 4303/4885 |
| US-20120069418-A1 | ELECTROCHROMIC FORMULATION, METHOD FOR THE PRODUCTION THEREOF, AND ORGANIC ELECTROCHROMIC COMPONENT | HCN2, EPX, HCN4 | HTT 2208/4885HTR1D 4005/4885HTR1B 3589/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | HTT 3178/4885HTR1D 4672/4885HTR1B 4042/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | HTT 493/4885HTR1D 3141/4885HTR1B 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.